公开(公告)号：US20230012321A1

公开(公告)日：2023-01-12

申请号：US17313679

申请日：2021-05-06

申请人： Arvinas Operations, Inc.

发明人： Laura E.N. ALLAN ,  Chungpin Herman CHEN ,  Hanqing DONG ,  Robert J. DUGUID ,  John A. GROSSO ,  Royal J. HASKELL, III ,  Casey Keith JAGER ,  Venkata A. KATTUBOINA ,  Aditya Mohan KAUSHAL ,  Samuel Elliott KENNEDY ,  Rhys LLOYD ,  Miranda Annell NEESER ,  Yuping QIU ,  Hayley REECE ,  Maxwell Marco REEVE ,  Joseph P. REO ,  Jerod ROBERTSON ,  Mohammad Mehdi ZAHEDI

IPC分类号： C07D401/14 ,  A61K9/00 ,  A61K9/20 ,  A61K45/06

摘要： The present disclosure relates to ultra-pure forms, polymorphs, amorphous forms, and formulations of N-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]-6-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl}methyl)piperidin-1-yl]pyridazine-3-carboxamide, referred to herein as Compound A: The present disclosure also relates methods of manufacturing and purifying the same, as well as intermediates useful in the synthesis of Compound A. The ultra-pure forms, polymorphs, amorphous forms, and formulations of Compound A can be used as therapeutic agents for the treatment of various diseases and conditions such as cancer.